Skip to main content
David Andorsky, MD, Oncology, Boulder, CO, Boulder Community Health

DavidJacobAndorskyMD

Oncology Boulder, CO

Physician

Dr. Andorsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Andorsky's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
  • Harvard Medical School
    Harvard Medical SchoolClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - Present
  • CO State Medical License
    CO State Medical License 2010 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell Lymphoma  
    Jeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology

Abstracts/Posters

  • Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
    David Andorsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and Exposition
    US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
  • US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and Exposition
    US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionDecember 5th, 2019
  • MAGNIFY Trial Shows Durability of Lenalidomide & Rituximab
    MAGNIFY Trial Shows Durability of Lenalidomide & RituximabNovember 10th, 2017
  • Join now to see all

Professional Memberships

Hospital Affiliations